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Abstract WONKA is a tool for the systematic analysis of
an ensemble of protein–ligand structures. It makes the
identification of conserved and unusual features within
such an ensemble straightforward. WONKA uses an intu-
itive workflow to process structural co-ordinates. Ligand
and protein features are summarised and then presented
within an interactive web application. WONKA’s power in
consolidating and summarising large amounts of data is
described through the analysis of three bromodomain
datasets. Furthermore, and in contrast to many current
methods, WONKA relates analysis to individual ligands,
from which we find unusual and erroneous binding modes.
Finally the use of WONKA as an annotation tool to share
observations about structures is demonstrated. WONKA is
freely available to download and install locally or can be
used online at http://wonka.sgc.ox.ac.uk.
Keywords Structure based drug design  Data driven
drug design  Bromodomains
Introduction
In recent years approaches to Structure Based Drug Design
(SBDD) and specifically Fragment Based Drug Design [1–
3] (FBDD) have developed extensively, resulting in a
rapidly increasing number of available liganded structures
for a given protein target. In the pharmaceutical industry it
is now commonplace to have access to many tens of
liganded crystal structures within a drug discovery pro-
gramme, leading to the rise of a new field of Ensemble
Based Drug Design [4], EBDD. A leading example of
which being Pitt et al.’s Polyphony [4], which generates
novel superimposition-dependent conformational analyses
of large numbers (hundreds) of crystal structures. In gen-
eral, however, computational tools have not kept pace with
the surge in availability of this data and the workhorse for
inspecting SBDD output remains generic structural biology
visualisation tools such as Pymol [5]. However, such tools
are designed toward the evaluation of at most a handful of
structures at any one time. Furthermore they do not, by
default, identify and highlight trends within a dataset that
can be used to inform SBDD. Analysis methods that are
available, e.g. pharmacophore model generation, produce
generalised models that do not refer directly back to each
ligand in an ensemble. Finally there is no approach
allowing the user to easily capture and share observations
of interest whilst inspecting structures. Any useful
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observations must be separately and manually added to
online encyclopaedias such as Proteopedia [6]. As a result
the inspection of SBDD output is currently a time con-
suming manual bottleneck, relying on the skill of the sci-
entist to remember features between structures, thereby
leading to repetitive, incomplete and subjective analyses.
Rather than acting as a bottleneck, the recent influx of
data should present an opportunity to develop novel tools
that present simple analyses of protein–ligand interactions
to enable EBDD. In this work we focus on three core areas,
ligand-based, residue-based and water-based analyses,
since these are three of the most commonly considered
structural biology analyses.
Ligand-based pharmacophore abstractions of structural
data are commonly used in computational chemistry [7, 8],
in large part by generating predictive three or four point
pharmacophores from a single or a handful of ligands.
These are useful for virtual screening exercises [9, 10],
however for analyses of ensembles of liganded structures
they present three major weaknesses. Firstly, they are by
definition simplistic and reductionist models that cannot
consider either the complete range of binding modes or
infrequently represented features in the data. Secondly, the
relative contribution of each ligand’s features to the phar-
macophore model is not readily apparent resulting in
analyses tending to be confined to broad trends, thereby
potentially missing information about interesting com-
pounds that do not fit general patterns. Thirdly, there is
normally no connection between the ligand-based phar-
macophore and its environment—interactions with protein
and water atoms.
Further to ligand-based pharmacophores, presenting an
overview of the effects of various ligands on residue con-
formation and water conservation/displacements are also
key areas of interest when studying protein–ligand inter-
actions [4, 11]. A number of tools exist to make predictions
about these effects, but, to our knowledge, none exist to
look for trends and extract important information from
existing experimental data. Molecular dynamics and crys-
tallographic methodologies [12] often cluster residue con-
formations to classify normal modes and residue
interconnectivity [13]. Equally, energetics calculations can
calculate the probability of waters being displaced [14, 15]
upon ligand binding. Family-wide analyses can determine
the likely spatial conservation of a given water ligand [16].
Each of these methods produces useful insights for SBDD,
however they suffer from two key weaknesses. Firstly, they
tend to be computationally expensive and complex,
requiring careful configuration for each novel target class.
Secondly, and most crucially, they are not designed with
the goal of analysing ensembles of liganded structures.
This means they are not able to directly refer their water-
based and residue-based analyses of the ensemble back to
the contributing ligands. It is the ability to not just identify
patterns, but to easily relate these observations to individ-
ual ligand complexes that represents a gap in current
computational capabilities.
To address these challenges we present WONKA, an
automated computational tool that provides a range of
analyses of protein–ligand structural ensembles. WONKA
summarises ligands within binding site clusters, presents a
pharmacophore-based analysis of core binding modes and
summarises changes in residue conformation and water
conservation across an ensemble of structures of the same
protein. WONKA differs from currently available methods
in three core ways. Firstly it presents combined ligand and
protein based analyses in a single and intuitive web-based
workflow. Secondly it relates these analyses at the level of
individual ligands allowing for specific and nuanced
interpretation. Finally the WONKA graphical user inter-
face facilitates data annotation and sharing.
Below we describe the WONKA method for finding,
consolidating and then visualising interesting features
within an ensemble of structures. We then outline WON-
KA’s use in performing target-level comparisons between
three Human bromodomain proteins. Finally we demon-
strate WONKA’s ability to find interesting and erroneously
modelled ligands within a dataset and then share these
observations broadly.
Method and materials
In this paper we present the analyses of the following
Human proteins: the second bromodomain of Human
Pleckstrin homology domain interacting protein (PHIP—
Uniprot Q8WWQ0), the bromodomain of Human bro-
modomain containing protein 1 (BRD1—Uniprot Q86X06)
and the bromodomain of Human bromodomain adjacent to
zinc finger domain 2B (BAZ2B—Uniprot Q9UIF8). The
datasets consist of 13, 29 and 33 structures respectively.
All are derived by X-ray crystallography and have a res-
olution better than 2.5 A˚. All datasets were collected and
analysed at the Diamond Light Source I04-1 beamline.
Structures were superposed using Molsoft ICM’s [17] all
residue based alignment method. The superposed struc-
tures for these targets are shown in Fig. 1. This form of
visualisation provides, at best, a very broad brush view of
features. For example, ligands bind in a well-defined
region of the protein, some residues present different
degrees of conformational change than others and there are
a number of conserved water positions. However it is non-
trivial to establish which ligands displace which waters, or
move which residues or indeed what pharmacophoric
features are most conserved and missing across the avail-
able ligands.
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Processing data
The WONKA processing method consists of four steps.
First, the PDB [18] files are parsed and the ligands
extracted using the RDKit [19] and stored in a Python [20]
Django [21] data model. Second, fragments and pharma-
cophores are generated from the bound ligands and these
are again stored in the data model. Third, waters, residues,
ligand pharmacophores, ligand fragments and ligands are
clustered in space and these clusters stored in the data
model. Finally any discovered features are taken from the
data model and displayed in an interactive web browser-
based application.
Input of data
The input for each target in WONKA is a single CSV file
and the relevant PDB files. The first row of the CSV is the
column header. Each subsequent row is a unique ligand-
bound protein chain for the target. Models are entered by
chain to allow comparison of ligands binding to different
chains in the asymmetric unit. If a ligand binds between
chains, either chain can be specified. The CSV file should
contain a full path to the PDB file for this chain and a
SMILES of the ligand bound to this chain, which has
assigned the appropriate tautomeric and charge state.
Additional information can be provided, including for
example the registration ID of this compound and the
unique model ID of this chain. An example file is available
as part of the WONKA distribution. The PDB files used in
this analysis should be pre-aligned to a template chain and
the residues should be numbered consistently across all
models. In this analysis MolSoft ICM was used, however
any protein alignment software can be used. WONKA can
then process the data using a simple command line
argument.
Pharmacophore formation and ligand
fragmentation
The chemistry of ligands within the available datasets is
expressed as pharmacophore and fragment-based abstrac-
tions. Ligand-based pharmacophores for all ligands are
generated using the standard SMARTS [22] -based RDKit
[19] pharmacophore definitions. Halogen and ring-methyl
group pharmacophores are also included due to their rele-
vance to medicinal chemistry [23, 24]. A singly substituted
non-polar carbon atom is defined as ‘‘Hydrophobe’’ in the
analysis below. Ligand-based fragments are generated using
the method of Hussain et al. [25] and stored as described
previously within our OOMMPPAA method [26].
Feature clustering
For a given target in WONKA it is not possible to pre-
determine the appropriate number of clusters for each
feature. However a physically interpretable distance can be
used to determine whether two features, e.g. two H-bond
acceptors, should or should not fall inside the same cluster.
For this reason the Dirichlet process (DP) Means algorithm
[27] was chosen. The DP Means algorithm is computa-
tionally efficient and does not require a pre-determined
number of clusters to be defined. Instead a single parameter
(k) is defined which determines the maximum distance
allowed between a point in a cluster and the cluster centre.
The values of k within WONKA were chosen based
upon visual inspection of the three bromodomain datasets
in this analysis. They were then validated using several
Fig. 1 The ensemble of liganded structures for Human PHIP, BRD1
and BAZ2B bromodomains respectively (left to right). The superim-
position of structures results in a visualisation which is extremely
difficult to interpret, especially when attempting to identify nuanced
changes presented in a minority of structures. Protein carbon in grey
and ligand carbon in yellow. Heteroatoms are coloured according to
Molsoft ICM colour scheme. Blue spheres are waters
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GSK datasets from diverse targets. For waters 1.5 A˚ was
chosen, for pharmacophores and fragments a value of
2.0 A˚ was chosen, for residues a value of 2.5 A˚ was chosen
and for ligands a value of 5.0 A˚ was chosen. Clusters are
determined and stored in the database for later use. For
waters, pharmacophores and molecules the Cartesian
coordinates of the unweighted centre of mass are employed
for clustering. For residues the all-against-all heavy atom
RMSDs between like-residues in the structural ensemble
are used. The k values chosen have been shown to be
broadly appropriate for the eight diverse targets analysed
by WONKA so far. However this may not be true for all
target classes. The parameter can be altered in the source
code before analysis takes place.
Visualisation
The visualisation component of WONKA, which runs
within modern web browsers, consists of four main com-
ponents: (A) the ‘‘Key Feature’’ and ‘‘Summary’’ panels for
selecting and displaying important clusters; (B) the 2D
compound display and selector; (C) the 3D protein com-
pound display; and (D) the annotation and download tool.
Key Feature and Summary Panel
The entry point to WONKA analysis is the ‘‘Key Feature’’
panel (Fig. 2a). The ‘‘Ligands’’ tab in the panel displays
the Pharmacophore information in the ‘‘Summary Panel’’,
shown in Fig. 2b. Each Pharmacophore cluster is displayed
as a row. They are shown in descending size order, so that
the most conserved pharmacophore is highlighted at the top
of the list. Clicking on each button displays the cluster
centre of mass as a star in the 3D viewer (Fig. 2c). Each
star is coloured by the pharmacophore point (e.g. red for
H-bond acceptors) and its size scaled according to the
percent conservation of this feature (i.e. a larger point is
more conserved). In Fig. 2c, the red acceptor feature is
more conserved than the blue donor feature or the brown
hydrophobe feature. On the right hand side of each row is a
grid of green and white buttons. Each column of this grid
represents a ligand. If the ligand presents the feature the
button is coloured green. If it does not it is coloured white.
Clicking on each button displays the ligand in the 3D
Viewer and colours the column border red, to indicate this
ligand is shown. This assists the user firstly in identifying a
consensus pharmacophore for the bound ligands and sec-
ondly in isolating ligands that have, or do not have, a given
pharmacophore feature.
The ‘‘Residues’’ tab displays all residues within 5.0 A˚ of
any ligand (by default in the most populated ligand cluster)
in descending order of maximum RMSD in the ‘‘Summary
Panel’’. For residues the panel on the right hand side is
coloured by the cluster this ligand moves this residue into.
An example of residue clustering for PHIP is shown in
Fig. 3. In Fig. 3a the ensemble of data is shown, from
which some changes in residue conformation can be seen.
However it is unclear which residues undergo the greatest
conformational changes, how many different conforma-
tions exist and which ligands are associated to each residue
conformational cluster. In Fig. 3b, WONKA highlights a
tyrosine residue that presents three distinct conformational
clusters (third in list). Clicking on the green, grey or purple
button (annotated ‘‘2’’) shows all the ligand conformations
Fig. 2 The entry point of the user interface for WONKA. a The ‘‘Key
Feature’’ panel. Clicking on each button generates a different
summary display in section b. b The ‘‘Summary Panel’’, in this case
for Key Pharmacophores. Each row is a different pharmacophore
cluster and each column is a different bound ligand. A green grid
element indicates the ligand contains the corresponding pharma-
cophore. c The 3D display. Ligands can be displayed here by left-
clicking on the corresponding column. Pharmacophore features are
shown—colour coded corresponding to b
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with this tyrosine in the green, grey or purple conformation
cluster. Clicking on the relevant ‘‘Show’’ button (annotated
‘‘3’’) highlights the three conformational clusters for this
residue (green and grey stick for carbon atoms) in the 3D
display. Equally, by clicking on each grey panel (Fig. 3b
annotated ‘‘4’’) for this tyrosine, the ligands related to the
grey conformation cluster are then shown in the 3D dis-
play. This example demonstrates how WONKA can effi-
ciently highlight residue conformational differences,
cluster them, and then relate them back to the relevant
ligands involved.
Conserved water positions are also explicitly considered
in WONKA. The ‘‘Water’’ button presents water clusters
within 1.5 A˚ of complexed ligands found in the largest
ligand cluster. The water clusters are then shown ordered
by the number of complexes associated to each cluster, i.e.
how conserved each water is. In Fig. 4a the ensemble of
water data available for BRD1 is shown, from which water
position conservation can be seen, however the extent of
conservation and displacement cannot be determined. In
Fig. 4b WONKA shows water clusters with [85 % con-
servation across the ensemble of models. Waters are shown
in the viewer with a radius of the fraction of conservation,
i.e. a water in a completely conserved location would be
represented with a red ball of radius 1 A˚. The ‘‘Summary
Panel’’ (inset Fig. 4b) indicates the ligands (columns) that
displace these waters as white grid boxes. For example
ligand three (column three) displaces the fifth, sixth and
seventh most conserved waters. In this example WONKA
has processed the ensemble information, as shown in
Fig. 4a, prioritised information about water position con-
servation and displacement and then displayed this in an
interactive 3D display.
Clicking on the ‘‘Sites’’ button presents ligand clusters.
Each cluster centre is presented as a coloured ball, corre-
sponding to the ‘‘Summary Panel’’. From the ‘‘Summary
Panel’’ the user can select all of the ligands binding in a
given site on the protein. Furthermore, pressing the
‘‘Analyse’’ button next to the site button presents the
WONKA analysis only for the region of this site in a new
browser tab. By default, analysis takes place for the main
site, so that only that site’s conserved waters and phar-
macophores are shown. For many targets allosteric binding
can be a powerful tool to modulate protein activity and
selectivity—indeed for both BRD1 and PHIP ligands were
found in multiple binding sites. Through the ‘‘Sites’’ button
the user can rapidly identify these allosteric binders and
then move onto the analysis of key residue movements and
water displacements, in each region.
The examples in Figs. 3 and 4 demonstrate how complex
ensemble data can be interpreted by WONKA via the ‘‘Key
Feature’’ panel. Selection of the relevant feature shows
filtered, informative data and visualisations in the ‘‘Sum-
mary Panel’’. From these summaries key insights can be
more easily found and used for further compound design.
2D and 3D display
The 2D ligand display shows all complexed ligands as 2D
depictions. Clicking on each 2D depiction toggles its
Fig. 3 Capturing and presenting interesting residue conformational
differences. a The complete ensemble of PHIP models is displayed.
Some residue conformational differences can be identified but cannot
be assigned to specific ligands. b WONKA clusters a particular
tyrosine’s conformations into green, grey and purple clusters. The
residue button (1), highlights each residue. Clicking on the green,
grey, or purple buttons, (2) shows only ligands in the green clus-
ter, grey cluster or purple cluster respectively. Clicking on the
‘‘Show’’ button (3) results in only the conformational clusters for
this residue being shown. Individual ligands can also be selected,
based on their cluster, by clicking the feature summary panel (4)
J Comput Aided Mol Des (2015) 29:963–973 967
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display on and off in the 3D display. Control-click toggles
the display of its complexed protein, shift-click its com-
plexed waters. Activity data can be added as outlined for
OOMMPPAA [26] and can be viewed by hovering over the
2D compound depictions. The ‘‘Order Chem’’ button sorts
the compounds based upon Morgan fingerprint [28] clus-
tering (radius 2) carried out using the RDKit Butina clus-
tering algorithm [29]. The 3D display is an interactive 3D
window for displaying the protein, ligands, waters and key
features and is powered by the activeICMJS 3D protein
viewer [30].
Structure annotation
A unique feature of the interactive portion of WONKA is
the ‘‘Annotation and Download Tool’’. This feature
improves upon earlier tools such as iSee [30, 31] and
ChromoHub [32], which have been used successfully to
annotate and summarise structural data and facilitate the
download of integrated datapacks. These tools, however,
require significant manual effort in generating observa-
tions. WONKA provides an easy-to-use and easy-to-share
tool for making such annotations, which reduces the time
spent on duplicated analyses of structural ensembles and
allows for expert analyses to be shared across the
community.
During the analysis of the structural ensemble in
WONKA a user can, at any point, capture an observation
using the ‘‘Save State’’ button below the 3D viewer, after
entering any comments they wish to share. This saves the
comment and the view in the back-end data model and
creates a unique URL to share this observation. An
example of this is shown in Fig. 5 and is accessible here:
http://bit.ly/19EVO21.
On the left hand side the Author, the Author’s Comment
and a 3D fully-interactive display of the view captured is
displayed. On the right hand side a Disqus [33] discussion
panel is presented allowing multiple users to comment and
discuss the observation in an online forum-like manner.
Observations can be filtered and selected for a specific
target. In the future, further meta-data will be provided to
filter the search on other factors, e.g. the author of the
comment, compound or residue shown. This capture,
comment and share feature of WONKA reduces duplica-
tion of analysis of ligand ensembles and can be used as a
training resource, highlighting the important features of
protein–ligand interactions for a given target.
Results and discussion
Below, we highlight examples of how WONKA can be
used with three Human bromodomain targets (BRD1, PHIP
and BAZ2B), using crystallographic data outlined in the
Methods (above). Firstly we demonstrate how water-based
analyses can compare and contrast these proteins. Secondly
we consider the ligand pharmacophoric differences of
PHIP and BRD1. Finally we use WONKA to find and then
annotate structures of interest for BRD1.
Water analysis of three bromodomains
Waters are key components in structure based drug design
and their displacement is often important in driving
potency and selectivity for many target classes [34, 35].
Bromodomains present an interesting example of water
conservation. A wide-ranging structural analysis of many
members of the bromodomain family has shown a
Fig. 4 Summarising conserved water locations and highlighting
displacements. a Displays all the waters for the BRD1 ensemble of
structures. Some conservation can be observed, but the extent of
conservation and any displacement by ligands cannot be seen.
b WONKA shows all waters as red balls, whose radius is proportional
to percentage conservation, that are at locations which are [85 %
conserved and within 1.5 A˚ of the ligands. From the size of the balls
the extent of conservation can be seen. From the ‘‘Summary Panel’’
(inset), the waters can be shown or hidden (1) and the ligands that
displace these waters are highlighted (white boxes) and can be
displayed (2)
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consistent pattern of four conserved waters at the bottom of
a conserved pocket which binds histone peptides [36, 37].
Much work has been done, experimentally and computa-
tionally [38, 39], to assess the importance of these waters.
In Fig. 6 WONKA screenshots are shown of the analysis
of the most conserved water-occupied positions for
BAZ2B, PHIP and BRD1 respectively. For BAZ2B and
BRD1 only waters conserved across 85 % or more struc-
tures are shown. For PHIP all conserved waters[50 % are
shown. In each case WONKA correctly identifies the four
conserved ‘‘bromodomain waters’’ [37] circled. The left
most ‘‘bromodomain water’’ for PHIP is smaller than the
other three. This indicates that it is less conserved, i.e. more
frequently displaced, than the other ‘‘bromodomain
waters’’. Through the ‘‘Summary Panel’’ WONKA can
then be used to identify which ligands displace this and
other waters, as discussed above.
WONKA also indicates the difference in water locations
for these targets. For example BRD1 has two further con-
served water positions closely connected to the four bro-
modomain waters and another further out of the pocket.
Conversely BAZ2B has two conserved water positions
placed more distantly and a further four out of the pocket.
In this example WONKA is able to summarise data from
multiple targets. It is able to correctly identify core water
structures, indicate which ligands displace these waters and
indicate subtle differences in water structures between
closely related targets. All of these insights could be
leveraged in SBDD programmes to develop more potent
and selective molecules.
Fig. 5 An example WONKA comment. Left, the fully interactive activeICMJS panel displaying the observation and comment (PDB code
4AMF). Right, the Disqus discussion allows for dialogue on this observation, including image upload and comment prioritisation by moderators
Fig. 6 The conserved water positions for BAZ2B, PHIP and BRD1
(left-to-right) are shown as red balls. The radius of the balls is
proportional to the fraction of conservation of the water cluster.
WONKA highlights the four conserved ‘‘bromodomain waters’’
(circled). It also demonstrates the remaining waters follow different
patterns for the targets. PHIP’s left most ‘‘bromodomain water’’ is
frequently displaced. BAZ2B presents conserved waters outside of
the peptide binding pocket. PDB IDs 4CUP, 3MB3 and 4AMF
respectively
J Comput Aided Mol Des (2015) 29:963–973 969
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PHIP and BRD1 pharmacophore comparison
WONKA can also be used to analyse and compare targets
based on ligand-based pharmacophores. Using the ‘‘Li-
gands’’ button the pharmacophoric conservation of ligands
bound to a target can be assessed. The five most conserved
pharmacophoric features for PHIP and BRD1 respectively
are shown in Fig. 7 from which two observations can be
made. Firstly it is immediately clear that less structural data
is available for PHIP (13 structures) than BRD1 (25
structures), since more columns are presented for BRD1.
Secondly, whilst the BRD1 ligand-set contains a highly
conserved acceptor feature—present in all but two
ligands—the PHIP ligand set does not contain any highly-
conserved pharmacophoric features. The pattern shown for
BRD1 is also seen for BAZ2B (data not shown) and is
commonly observed across many bromodomains, where an
H-bond acceptor is placed forming an interaction with the
terminal amide of a conserved asparagine residue [36].
This asparagine residue is not conserved in PHIP, instead it
is replaced with a threonine residue. The top-most acceptor
cluster in Fig. 7a interacts with this threonine via a water-
mediated hydrogen bond, however it is not essential for
binding. Investigation of the data indicates that ligands
interact with the threonine in a multitude of binding con-
figurations, forming a range of H-bond donor and acceptor
interactions, some water mediated. In this example
WONKA summarised the key pharmacophores for a set of
ligands. Comparison of these pharmacophores highlighted
differences between two closely related but crucially dif-
ferent targets. Further, in the case of PHIP, WONKA acts
as an entry point for categorising ligands into different
interactions with the important threonine residue.
Finding uniquely bound ligands for BRD1
The ‘‘Summary Panel’’ in Fig. 7b shows that there are only
two ligands that lack the most conserved H-bond acceptor
for BRD1 (as represented by the two white grid elements in
first row). As discussed, this acceptor is a very commonly
found feature within bromodomain inhibitors as it forms a
critical H-bond with the conserved asparagine residue [40].
WONKA can be used to display these two ligands for
further detailed investigation.
Analysing the ligands through WONKA presents two
different stories. By clicking the ‘‘Sites’’ button in the
‘‘Key Feature’’ panel it can be shown that the first ligand
binds in an alternative site to the main cluster (data not
shown). This ligand would therefore be a candidate for
exploring allosteric binding. In contrast, the second ligand
binds as expected in the bromodomain peptide binding
pocket. However, as shown in Fig. 8c it binds deeper into
the pocket, displacing a conserved water molecule and
forming a hydrogen bond with a tyrosine residue. In Fig. 8a
we show the ‘‘Waters’’ ‘‘Summary Panel’’ for BRD1, with
this ligand highlighted in red. Figure 8a shows it has dis-
placed the fourth most conserved water, and is the only
ligand in the set to displace it. In this example WONKA
quickly indicates two interesting features related to this
ligand and BRD1 more generally. The above observations
could be of interest to other members of the community.
WONKA’s observation capture, annotation and sharing
tool was therefore used and the comment is available at the
following URL: http://bit.ly/19EVO21.
Error detection for BRD1
WONKA can also be used for detecting and reporting
possible errors in crystallographic refinement. A previous
version of the ‘‘Ligands’’ ‘‘Summary Panel’’ for BRD1 is
shown in Fig. 9a. The column outlined in red corresponds
to the ligand shown in Fig. 9b and indicates it is missing
the acceptor, hydrophobe and ring methyl pharmacophores
in the BRD1 ligand set, found in many other ligands in the
set. Figure 9c shows these key groups as red (acceptor) and
brown (hydrophobe group) stars. The positioning of the
Fig. 7 The pharmacophoric conservation comparison between
a PHIP and b BRD1. Firstly the greater number of columns in the
‘‘Summary Panel’’ for BRD1 shows that there is less structural data
available for PHIP (13 structures) than BRD1 (25 structures).
Secondly, whilst BRD1 contains a highly conserved acceptor feature
(first row)—present in all but two ligands—PHIP does not. WONKA
allows the user to scrutinise the ligands missing the conserved
features by clicking on the appropriate (white) grid box
970 J Comput Aided Mol Des (2015) 29:963–973
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features in Fig. 9c indicate that rotation of the terminal
carbonyl 180 degrees would satisfy both of these phar-
macophore groups. A report of this observation within
WONKA can be seen here: http://bit.ly/1C4BMIM. Errors
of this nature are easy to miss, particularly for crystallog-
raphers unfamiliar with the important binding interactions
of a particular target. WONKA makes is easier to identify,
highlight and share such issues.
The above examples demonstrate ways in which
WONKA can be used quickly and objectively to sum-
marise large and varied ensemble datasets such as those
shown in Fig. 1. Key ligand-based, water-based and resi-
due-based features can be observed and then compared
between targets. These comparisons may be employed by
medicinal chemistry to create potent and selective com-
pounds. Secondly WONKA can be used to quickly find and
summarise interesting and erroneous compounds. These
observations can then be shared around the community,
trivially, using WONKA’s in-built reporting mechanism.
Conclusion
In this paper we present WONKA, an automated and freely
available web-based computational tool to provide analysis
of protein–ligand structural ensembles. WONKA aims to
consolidate the varied data from an ensemble of liganded
structures and provide focussed summaries of this data.
These summaries can then be used to describe and compare
targets and find erroneous or interesting ligands. This
analysis is not trivial using currently available techniques.
WONKA also provides a novel data annotation and
reporting tool that is, to our knowledge, currently unique
within the structural biology community.
WONKA differs from existing tools in three key ways.
Firstly it produces combined analyses in a single and
intuitive workflow. Secondly it directly relates these anal-
yses to individual ligands allowing for nuanced analysis.
Finally WONKA facilitates data annotation and the sharing
of these annotations through a unique data capture and
Fig. 8 An unusual ligand for BRD1, highlighted in a red outline in
(a). This also shows it lacks the fourth most conserved water and is
the only ligand to do so in the data set. b The selected ligand in 2D.
c The 3D view of this ligand’s binding mode (PDB code 4AMF). The
red star indicates the position of the most conserved acceptor it lacks.
The link to observe this within a WONKA comment is available at
the following URL: http://bit.ly/19EVO21
Fig. 9 The ligand bound to BRD1 was incorrectly modelled.
a WONKA shows the red highlighted ligand misses three of the six
most conserved pharmacophores. b The 2D depiction of this ligand.
c Indicates that rotation of the terminal carbonyl 180 would satisfy
the conserved acceptor pharmacophore (PDB code 4AME).
A WONKA comment for this is available here: http://bit.ly/
1C4BMIM
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storage feature. We have shown varied examples of
WONKA’s ability to concisely highlight useful informa-
tion from large ensembles of structure. From this, evi-
dence-based decisions on future compound design and
structural refinement can be made. For these reasons
WONKA may serve as an invaluable tool at the initial
stages of SBDD and FBDD programmes. WONKA is
available to try online or to install locally at http://wonka.
sgc.ox.ac.uk/WONKA/.
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